There is growing interest in the use of procalcitonin as a biomarker of bacterial infection. In particular, focus has been on the use of procalcitonin to facilitate a more timely diagnosis of sepsis and to guide the appropriate duration of antibiotic therapy. However, there is a lack of consensus in the literature concerning the role of measuring procalcitonin levels in clinical practice. This article reviews the evidence surrounding the utility of this biomarker for patients with sepsis in the intensive care environment. It is concluded that raised procalcitonin levels add little as a diagnostic criterion, however evidence supports the incorporation of procalcitonin-based algorithms relating to antibiotic stewardship in this patient population.
AssicotMGendrelDCarsinH. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet1993;341: 515–18.
2.
VincentJLSakrYSprungCL. Sepsis in European Intensive Care units: Results of the SOAP study. Crit Care Med2006;34: 344–53.
3.
LevyMMDellingerRPTownsendSR. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med2010;36: 222–31.
4.
BeckerJUTheodosisCJacobST. Surviving sepsis in low-income and middle-income countries: new directions for care and research. Lancet Infect Dis2009;9: 577–82.
5.
LuytC-EChastreJ. Plasma Procalcitonin: Another arrow in our quiver?Respiratory Care2011;56: 530–32.
6.
FaixJD. Using procalcitonin to diagnose sepsis and the potential for improved antibiotic stewardship. Med Lab Observ2008;40: 25–26.
7.
MüllerBWhiteJCNylénES. Ubiquitous expression of the calcitonin—i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab2001;86: 396–404.
8.
GilbertD. Serum procalcitonin levels. It is all about confidence. Arch Intern Med2012;172: 722–23.
9.
CharlesPELadoireSAhoS. Serum procalcitonin elevation in critically ill patients at the onset of bacteraemia caused by either Gram negative or Gram positive bacteria. BMC Infect Dis2008;8: 38–46.
10.
KoivulaIHämäläinenSJantunenE. Elevated procalcitonin predicts gram-negative sepsis in haematological patients with febrile neutropenia. Scand J Infect Dis2011;43: 471–78.
11.
RiedelS. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diag Microbiol Infect Dis2012;73: 221–27.
12.
LiappisAPGibbsKWYoonB. Human leukocyte and whole blood cytokine response to exogenous procalcitonin. The 89th Endocrine Society Meeting. Toronto, Canada, June 2007 [Abstract P1–367].
13.
MaierMWutzlerSLehnertM. Serum procalcitonin levels in patients with multiple injuries including visceral trauma. J Trauma2009;66: 243–49.
14.
PicarielloCLazzeriCChiostriM. Procalcitonin in patients with acute coronary syndromes and cardiogenic shock submitted to percutaneous coronary intervention. Intern Emerg Med2009;4: 403–08.
15.
SchuetzPAffolterBHunzikerS. Serum procalcitonin, C-reactive protein and white blood cell levels following hypothermia after cardiac arrest: a retrospective cohort study. Eur J Clin Invest2010;40: 376–81.
16.
Bonaci-NikolicBJeremicINikolicM. High procalcitonin in a patient with drug hypersensitivity syndrome. Intern Med2009;48: 1471–74.
17.
WannerGAKeelMSteckholzerU. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure and mortality in injured patients. Crit Care Med2000;28: 950–57.
18.
JapiassuAMBozzaFA. The many facets of procalcitonin in the critically ill population. Crit Care Med2012;40: 2903–05.
19.
ReynoldsSCShorrAFMuscedereJ. Longitudinal changes in procalcitonin in a heterogeneous group of critically ill patients. Crit Care Med2012;40: 2781–87.
20.
LevyMMFinkMPMarshallJC. 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Crit Care Med2003;31: 1250–56.
21.
DellingerRPLevyMMCarletJM. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock. Crit Care Med2008;36: 296–327.
22.
Members of the American College of Chest Physicians / Society of Critical Care Medicine consensus conference committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med1992;20: 864–74.
23.
TangBMEslickGDCraigJCMcCleanAS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis2007;7: 210–17.
24.
KumarARobertsDWoodKE. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med2006;34: 1589–96.
25.
Rangel-FraustoMSPitletDCostiganM. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA1995;273: 117–23.
26.
MagadiaRRWeinsteinMP. Laboratory diagnosis of bacteremia and fungemia. Infect Dis Clin North Am2001;15: 1009–24.
27.
ChanTGuF. Early diagnosis of sepsis using serum biomarkers. Expert Rev Mol Diagn.2011;11: 487–96.
28.
PierrakosCVincentJL. Sepsis biomarkers: a review. Crit Care2010;14: R15.
29.
PovaPAlmeidaEMoreiraP. C-reactive protein as an indicator of sepsis. Intensive Care Med1998;24: 1052–56.
30.
ShimetaniNShimetaniKMoriM. Clinical evaluation of the measurement of serum procalcitonin and serum amyloid A protein in patients with high and low concentrations of serum C-reactive protein. Scand J Clin Lab Invest2004;64: 469–74.
31.
KofoedKAndersenOKronborgG. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care2007;11: R38.
32.
MannEAWoodGLWadeCE. Use of procalcitonin for the detection of sepsis in the critically ill burn patient: A systematic review of the literature. Burns2011;37: 549–58.
33.
KimMHLimGKangSY. Utility of procalcitonin as an early diagnostic marker of bacteremia in patients with acute fever. Yonsei Med J.2011;52: 276–81.
34.
LaiCCTanCKChenSY. Diagnostic performance of procalcitonin for bacteremia in patients with bacterial infection at the emergency department. J Infect2010;61: 512–15.
35.
CharlesPELadoireSSnauwaertA. Impact of previous sepsis on the accuracy of procalcitonin for the early diagnosis of blood stream infection in critically ill patients. BMC Infectious Diseases2008;8: 163.
36.
UzzanBCohenRNicolasP. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med2006;34: 1996–2003.
37.
Ruiz-AlvarezMJGarcia-ValdecasasSDe PabloR. Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. J Intensive Care Med2009;24: 63–71.
38.
PrietoBAlvarezFV. Lack of transferability of results between procalcitonin assays. Clin Chem2009;55: 2226–27.
39.
TrompMLansdorpBBleeker-RoversCP. Serial and panel analyses of biomarkers do not improve the prediction of bacteremia compared to one procalcitonin measurement. J Infect2012;65: 292–301.
40.
Christ-CrainMJaccard-StolzDBingisserR. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet2004;363: 600–07.
41.
SchuetzPChrist-CainMWolbersM. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res2007;7: 102.
42.
NobreVHarbarthSGrafJ-D. Use of procalcitonin to shorten antibiotic treatment duration in septic patients. A randomized trial. Am J Respir Crit Care Med2008;177: 498–505.
43.
VenkateshBKennedyPKrugerPS. Changes in serum procalcitonin and C-reactive protein following antimicrobial therapy as a guide to antibiotic duration in the critically ill: a prospective evaluation. Anaesth Intensive Care2009;37: 20–26.
44.
HochreiterMKohlerTSchweigerAM. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care2009;13: R83.
45.
BouadmaLLuytC-ETubachF. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet2010;375: 463–74.
46.
KopteridesPSiemposIITsangarisI. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: A systematic review and meta-analysis of randomized controlled trials. Crit Care Med2010;38: 2229–41.
47.
HeylandDKJohnsonAPReynoldsSC. Procalcitonin for reduced antibiotic exposure in the critical care setting: A systematic review and economic evaluation. Crit Care Med2011;39: 1792–99.
48.
SchuetzPMüllerBChrist-CrainM. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infection. Cochrane Database Systematic rev2012 (9) CD007498.
49.
KarlssonSHeikkinenMPettiläV. Predictive value of procalcitonin decreases in patients with severe sepsis: a prospective observational study. Crit Care2010;14: R205.
50.
GeorgopoulouA-PSavvaAGiamarellos-BourboulisEJ. Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. J Crit Care2011;26: 331e1–331e7.
51.
TsangarisIPlachourasDKavathaD. Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infect Dis2009;9: 213.
